Actionable news
0
All posts from Actionable news
Actionable news in VRX: VALEANT PHARMACEUTICALS INTERNATIONAL,

Keep Watching Clovis Oncology

Clovis Oncology is still flying higher. After winning approval on December 19 for rucaparib, a drug for treating ovarian cancer, investors should brace for a secondary offering. The company has only $8.32 per share in cash.

Debt is another concern.

The debt/equity is nearly...


More